Jacqueline Pei1, Georgina Juniper1, Nynke S van den Berg1, Naoki Nisho1, Trevor Broadt2, Anthony R Welch3, Grace S Yi1, Roan C Raymundo1, Stefania U Chirita1, Guolan Lu1, Giri Krishnan1, Yu-Jin Lee1, Shrey Kapoor1, Quan Zhou1,4, A Dimitrios Colevas1, Natalie S Lui5, George A Poultsides6, Gordon Li4, Kurt R Zinn7, Eben L Rosenthal8. 1. Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, 900 Blake Wilbur Drive, Stanford, CA, 94305, USA. 2. Biopharmaceutical Development Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 3. Biological Resources Branch/DTP/DCTD, National Cancer Institute, Frederick, MD, USA. 4. Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA. 5. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA. 6. Department of Surgery, Section of Surgical Oncology, Stanford University School of Medicine, Stanford, CA, USA. 7. Department of Radiology, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA. 8. Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, 900 Blake Wilbur Drive, Stanford, CA, 94305, USA. elr@stanford.edu.
Abstract
PURPOSE: The development of molecularly targeted tracers is likely to improve the accuracy of diagnostic, screening, and therapeutic tools. Despite the many therapeutic antibodies that are FDA-approved with known toxicity, only a limited number of antibody-dye conjugates have been introduced to the clinic. Thorough evaluation of the safety, stability, and pharmacokinetics of antibody conjugates in the clinical setting compared with their parental components could accelerate the clinical approval of antibodies as agents for molecular imaging. Here we investigate the safety and stability of a near-infrared fluorescent dye (IRDye800CW) conjugated panitumumab, an approved therapeutic antibody, and report on the product stability, pharmacokinetics, adverse events, and QTc interval changes in patients. PROCEDURES: Panitumumab-IRDye800CW was made under good manufacturing practice (GMP) conditions in a single batch on March 26, 2014, and then evaluated over 4.5 years at 0, 3, and 6 months, and then at 6-month intervals thereafter. We conducted early phase trials in head and neck, lung, pancreas, and brain cancers with panitumumab-IRDye800CW. Eighty-one patients scheduled to undergo standard-of-care surgery were infused with doses between 0.06 to 2.83 mg/kg of antibody. Patient ECGs, blood samples, and adverse events were collected over 30-day post-infusion for analysis. RESULTS: Eighty-one patients underwent infusion of the study drug at a range of doses. Six patients (7.4 %) experienced an adverse event that was considered potentially related to the drug. The most common event was a prolonged QTc interval which occurred in three patients (3.7 %). Panitumumab-IRDye800CW had two OOS results at 42 and 54 months while meeting all other stability testing criteria. CONCLUSIONS: Panitumumab-IRDye800CW was safe and stable to administer over a 54-month window with a low rate of adverse events (7.4 %) which is consistent with the rate associated with panitumumab alone. This data supports re-purposing therapeutic antibodies as diagnostic imaging agents with limited preclinical toxicology studies.
PURPOSE: The development of molecularly targeted tracers is likely to improve the accuracy of diagnostic, screening, and therapeutic tools. Despite the many therapeutic antibodies that are FDA-approved with known toxicity, only a limited number of antibody-dye conjugates have been introduced to the clinic. Thorough evaluation of the safety, stability, and pharmacokinetics of antibody conjugates in the clinical setting compared with their parental components could accelerate the clinical approval of antibodies as agents for molecular imaging. Here we investigate the safety and stability of a near-infrared fluorescent dye (IRDye800CW) conjugated panitumumab, an approved therapeutic antibody, and report on the product stability, pharmacokinetics, adverse events, and QTc interval changes in patients. PROCEDURES: Panitumumab-IRDye800CW was made under good manufacturing practice (GMP) conditions in a single batch on March 26, 2014, and then evaluated over 4.5 years at 0, 3, and 6 months, and then at 6-month intervals thereafter. We conducted early phase trials in head and neck, lung, pancreas, and brain cancers with panitumumab-IRDye800CW. Eighty-one patients scheduled to undergo standard-of-care surgery were infused with doses between 0.06 to 2.83 mg/kg of antibody. Patient ECGs, blood samples, and adverse events were collected over 30-day post-infusion for analysis. RESULTS: Eighty-one patients underwent infusion of the study drug at a range of doses. Six patients (7.4 %) experienced an adverse event that was considered potentially related to the drug. The most common event was a prolonged QTc interval which occurred in three patients (3.7 %). Panitumumab-IRDye800CW had two OOS results at 42 and 54 months while meeting all other stability testing criteria. CONCLUSIONS: Panitumumab-IRDye800CW was safe and stable to administer over a 54-month window with a low rate of adverse events (7.4 %) which is consistent with the rate associated with panitumumab alone. This data supports re-purposing therapeutic antibodies as diagnostic imaging agents with limited preclinical toxicology studies.
Authors: Eva J Ter Weele; Anton G T Terwisscha van Scheltinga; Matthijs D Linssen; Wouter B Nagengast; Ingo Lindner; Annelies Jorritsma-Smit; Elisabeth G E de Vries; Jos G W Kosterink; Marjolijn N Lub-de Hooge Journal: Eur J Pharm Biopharm Date: 2016-05-12 Impact factor: 5.571
Authors: John C Marston; Gregory D Kennedy; Suzanne E Lapi; Yolanda E Hartman; Morgan T Richardson; Himani M Modi; Jason M Warram Journal: J Surg Res Date: 2019-02-22 Impact factor: 2.192
Authors: Laetitia E Lamberts; Maximillian Koch; Johannes S de Jong; Arthur L L Adams; Jürgen Glatz; Mariëtte E G Kranendonk; Anton G T Terwisscha van Scheltinga; Liesbeth Jansen; Jakob de Vries; Marjolijn N Lub-de Hooge; Carolien P Schröder; Annelies Jorritsma-Smit; Matthijs D Linssen; Esther de Boer; Bert van der Vegt; Wouter B Nagengast; Sjoerd G Elias; Sabrina Oliveira; Arjen J Witkamp; Willem P Th M Mali; Elsken Van der Wall; Paul J van Diest; Elisabeth G E de Vries; Vasilis Ntziachristos; Gooitzen M van Dam Journal: Clin Cancer Res Date: 2016-11-09 Impact factor: 12.531
Authors: Kristine E Day; Lauren N Beck; Nicholas L Deep; Joy Kovar; Kurt R Zinn; Eben L Rosenthal Journal: Laryngoscope Date: 2013-04-24 Impact factor: 3.325
Authors: Kip P Conner; Brooke M Rock; Gayle K Kwon; Joseph P Balthasar; Lubna Abuqayyas; Larry C Wienkers; Dan A Rock Journal: Drug Metab Dispos Date: 2014-09-10 Impact factor: 3.922
Authors: Naoki Nishio; Nynke S van den Berg; Stan van Keulen; Brock A Martin; Shayan Fakurnejad; Nutte Teraphongphom; Stefania U Chirita; Nicholas J Oberhelman; Guolan Lu; Crista E Horton; Michael J Kaplan; Vasu Divi; A Dimitrios Colevas; Eben L Rosenthal Journal: Nat Commun Date: 2019-11-06 Impact factor: 14.919
Authors: Rebecca W Gao; Nutte Teraphongphom; Esther de Boer; Nynke S van den Berg; Vasu Divi; Michael J Kaplan; Nicholas J Oberhelman; Steven S Hong; Elissa Capes; A Dimitrios Colevas; Jason M Warram; Eben L Rosenthal Journal: Theranostics Date: 2018-03-28 Impact factor: 11.556
Authors: Rahul Pal; Marisa E Hom; Nynke S van den Berg; Thinzar M Lwin; Yu-Jin Lee; Andrey Prilutskiy; William Faquin; Eric Yang; Srinivas V Saladi; Mark A Varvares; Eben L Rosenthal; Anand T N Kumar Journal: Clin Cancer Res Date: 2022-06-01 Impact factor: 13.801
Authors: Giri Krishnan; Nynke S van den Berg; Naoki Nishio; Shrey Kapoor; Jaqueline Pei; Laura Freeman; Yu-Jin Lee; Quan Zhou; Stan van Keulen; Shayan Farkurnejad; James Condon; Fred M Baik; Brock A Martin; Eben L Rosenthal Journal: J Nucl Med Date: 2022-01-13 Impact factor: 11.082
Authors: Quan Zhou; Nynke S van den Berg; Eben L Rosenthal; Michael Iv; Michael Zhang; Johana C M Vega Leonel; Shannon Walters; Naoki Nishio; Monica Granucci; Roan Raymundo; Grace Yi; Hannes Vogel; Romain Cayrol; Yu-Jin Lee; Guolan Lu; Marisa Hom; Wenying Kang; Melanie Hayden Gephart; Larry Recht; Seema Nagpal; Reena Thomas; Chirag Patel; Gerald A Grant; Gordon Li Journal: Theranostics Date: 2021-05-21 Impact factor: 11.556
Authors: Giri Krishnan; Nynke S van den Berg; Naoki Nishio; Georgina Juniper; Jaqueline Pei; Quan Zhou; Guolan Lu; Yu-Jin Lee; Kimberly Ramos; Andrei H Iagaru; Fred M Baik; Alexander D Colevas; Brock A Martin; Eben L Rosenthal Journal: Theranostics Date: 2021-05-24 Impact factor: 11.556